<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Droperidol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Droperidol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Droperidol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12424" href="/d/html/12424.html" rel="external">see "Droperidol: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13257" href="/d/html/13257.html" rel="external">see "Droperidol: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708711"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Arrhythmias:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving droperidol at doses at or below recommended doses. Some cases have occurred in patients with no known risk factors for QT prolongation, and some cases have been fatal.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to its potential for serious proarrhythmic effects and death, reserve droperidol for use in the treatment of patients who fail to show an acceptable response to other adequate treatments, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs.</p>
<p style="text-indent:-2em;margin-left:2em;">Cases of QT prolongation and serious arrhythmias (eg, torsade de pointes) have been reported in patients treated with droperidol. Based on these reports, all patients should undergo a 12-lead ECG prior to administration of droperidol to determine if a prolonged QT interval (ie, QTc greater than 440 msec for males or 450 msec for females) is present. If there is a prolonged QT interval, do not administer droperidol. For patients in whom the potential benefit of droperidol treatment is felt to outweigh the risks of potentially serious arrhythmias, perform ECG monitoring prior to treatment and continue for 2 to 3 hours after completing treatment to monitor for arrhythmias.</p>
<p style="text-indent:-2em;margin-left:2em;">Droperidol is contraindicated in patients with known or suspected QT prolongation, including patients with congenital long QT syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">Administer droperidol with extreme caution to patients who may be at risk for development of prolonged QT syndrome (eg, congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). Other risk factors may include age greater than 65 years, alcohol abuse, and use of agents such as benzodiazepines, volatile anesthetics, and IV opiates. Initiate droperidol at a low dose and adjust upward, with caution, as needed to achieve the desired effect.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F163613"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiemetic;</li>
<li>
                        First Generation (Typical) Antipsychotic</li></ul></div>
<div class="block doa drugH1Div" id="F163578"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Monitor vital signs and ECG at baseline and routinely.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8d33630-e330-4cf8-b396-8cd618cbc2d0">Acute undifferentiated agitation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute undifferentiated agitation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> Initial: 5 to 10 mg, as monotherapy or in combination with a benzodiazepine; wait at least 10 to 30 minutes before providing additional medications for agitation if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25395689','lexi-content-ref-20868907','lexi-content-ref-16282517','lexi-content-ref-1554179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25395689','lexi-content-ref-20868907','lexi-content-ref-16282517','lexi-content-ref-1554179'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 2.5 to 10 mg, as monotherapy or in combination with a benzodiazepine; may repeat droperidol dose every 5 minutes until sedation achieved; maximum dose 20 mg per episode; median required dose was 10 mg in one study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22981685','lexi-content-ref-16387219','lexi-content-ref-27745766','lexi-content-ref-1554179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22981685','lexi-content-ref-16387219','lexi-content-ref-27745766','lexi-content-ref-1554179'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8e0f4139-8e9d-4932-bcd0-1a652bdcc90f">Postoperative nausea and vomiting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting (PONV):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 0.625 to 1.25 mg administered at the end of procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18042859']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18042859'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Manufacturer labeling: Dosing in the prescribing information may not reflect current clinical practice.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM/IV: </b>Maximum initial dose: 2.5 mg; additional doses of 1.25 mg may be administered with caution to achieve desired effect.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991081"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50988366"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F163579"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Avoid for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. If used, consider deprescribing attempts to assess continued need and/or lowest effective dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing; use reduced initial dose.</p></div>
<div class="block dop drugH1Div" id="F163598"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13257" href="/d/html/13257.html" rel="external">see "Droperidol: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">Dosage must be individualized based on age, body weight, underlying medical conditions, physical status, concomitant medications, type of anesthesia, and surgical procedure.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b42cfd10-bab1-41c8-b61d-40deaf46112c">Agitation, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation, acute:</b> Limited data available; dosing regimen variable; optimal dose not established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11063369','lexi-content-ref-37317809','lexi-content-ref-35490341','lexi-content-ref-20401969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11063369','lexi-content-ref-37317809','lexi-content-ref-35490341','lexi-content-ref-20401969'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing: </i>Children ≥7 years and Adolescents: IM, IV: 0.1 to 0.2 mg/kg/dose; maximum dose: 10 mg/dose; dosing based on management of prehospital agitation by emergency medical services (n=96) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30380965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30380965'])">Ref</a></span>). <b>Note:</b> Although not described in the trial, may also administer IV if route is feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20401969','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20401969','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥7 years and Adolescents: May repeat dose in 15 to 30 minutes if no response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11063369','lexi-content-ref-9473921']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11063369','lexi-content-ref-9473921'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;34 kg: IM, IV: 0.625 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">34 to 57 kg: IM, IV: 1.25 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;57 to 68 kg: IM, IV: 1.875 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;68 kg: IM, IV: 2.5 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">Dosing reported in an inpatient psychiatric setting to manage agitation in patients (n=26) with an underlying psychiatric disorder. <b>Note: </b> Although not described in the trial, may also administer IV if route is feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11063369','lexi-content-ref-20401969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11063369','lexi-content-ref-20401969'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e1d082a-1c34-4bca-82e2-215c7a96587f">Postoperative nausea and vomiting; rescue treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting (PONV); rescue treatment:</b>
<b>Note:</b> Not routinely used for prevention; however, droperidol may be necessary as rescue therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: IM, IV: 0.01 to 0.075 mg/kg/dose; maximum dose: 1.25 mg/dose; administer additional doses with extreme caution and only if potential benefit outweighs risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512','lexi-content-ref-Mokha.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512','lexi-content-ref-Mokha.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51094245"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51094246"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F163544"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (including ventricular arrhythmia), hypotension (Chase 2002), prolonged QT interval on ECG (Cole 2020), tachycardia, torsades de pointes (Cole 2020), ventricular tachycardia (Takechi 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (Lim 1999), chills, depression, dizziness (Henzi 2000), drowsiness (Henzi 2000), dysphoria (Lim 1999), extrapyramidal reaction (including akathisia, dystonia) (Melnick 1988), hallucination, hyperactive behavior, neuroleptic malignant syndrome (So 2001), restlessness (Henzi 2000), sedated state (Henzi 2000), shivering, vertigo (Henzi 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, respiratory depression (Ramsden 2022)</p></div>
<div class="block coi drugH1Div" id="F163558"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to droperidol or any component of the formulation; known or suspected QT prolongation, including congenital long QT syndrome (prolonged QT<sub>c</sub> is defined as &gt;440 msec in males or &gt;450 msec in females)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Not for use in children ≤2 years of age</p></div>
<div class="block war drugH1Div" id="F163541"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Arrhythmias: Use extreme caution in patients with bradycardia (&lt;50 bpm), cardiac disease, concurrent MAO inhibitor therapy, Class I and Class III antiarrhythmics or other drugs known to prolong QT interval, and electrolyte disturbances (hypokalemia or hypomagnesemia), including concomitant drugs which may alter electrolytes (diuretics).</p>
<p style="text-indent:-2em;margin-left:4em;">• Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems. Relative to other antipsychotics, droperidol has a low potency of cholinergic blockade (Richelson 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; risk increases with age. Use with caution in patients at risk for aspiration pneumonia (eg, Alzheimer disease), particularly in patients &gt;75 years (Herzig 2017; Maddalena 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">• Extrapyramidal symptoms: May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics; frequencies reported are similar to placebo). Risk of dystonia (and possibly other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Factors associated with greater vulnerability to tardive dyskinesia include older in age, female gender combined with postmenopausal status, Parkinson disease, pseudoparkinsonism symptoms, affective disorders (particularly major depressive disorder), concurrent medical diseases such as diabetes, previous brain damage, alcohol use disorder, poor treatment response, and use of high doses of antipsychotics (APA [Keepers 2020]; Soares-Weiser 2007). Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability (Landi 2005; Seppala 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperprolactinemia: May increase prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown (Bargiota 2013; Froes Brandao 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuroleptic malignant syndrome (NMS): Use may be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity and/or autonomic instability.</p>
<p style="text-indent:-2em;margin-left:4em;">• Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).</p>
<p style="text-indent:-2em;margin-left:4em;">• Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma: Use with caution in patients with pheochromocytoma; severe hypertension and/or tachycardia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcohol use disorder, or concurrent therapy with medications which may lower seizure threshold (Chase 2002).</p></div>
<div class="block foc drugH1Div" id="F163552"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg/mL (2 mL)</p></div>
<div class="block geq drugH1Div" id="F163537"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323124"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (droPERidol Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/mL (per mL): $5.37</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F163555"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IM, IV:</b> Administer IM or IV; according to the manufacturer, IV push administration should be slow.</p></div>
<div class="block admp drugH1Div" id="F52612647"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Administer undiluted IM or by slow IV injection over 2 to 5 minutes.</p></div>
<div class="block use drugH1Div" id="F163554"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Postoperative nausea/vomiting (PONV)</b>: Prevention and/or treatment of nausea and vomiting from surgical and diagnostic procedures</p></div>
<div class="block off-label drugH1Div" id="F49508732"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute undifferentiated agitation</p></div>
<div class="block mst drugH1Div" id="F163621"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">DroPERidol may be confused with droNABinol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299238"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F163546"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Injection): May enhance the QTc-prolonging effect of DroPERidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-Parkinson Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible. If antipsychotic use is necessary, consider using atypical antipsychotics such as clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: DroPERidol may enhance the adverse/toxic effect of Bromopride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline: May diminish the therapeutic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: DroPERidol may enhance the CNS depressant effect of ChlorproMAZINE. DroPERidol may enhance the QTc-prolonging effect of ChlorproMAZINE.  Management: Consider alternatives to this drug combination. If combined, dose reductions are recommended. Monitor for additive toxicities such as QTc interval prolongation, ventricular arrhythmias, and CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Clarithromycin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: DroPERidol may enhance the CNS depressant effect of CNS Depressants.  Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Donepezil: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Fexinidazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Huperzine A: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: DroPERidol may enhance the CNS depressant effect of Methadone. DroPERidol may enhance the QTc-prolonging effect of Methadone.  Management: Consider alternatives. If combined, dose reductions are recommended. Monitor for additive toxicities such as QTc interval prolongation, ventricular arrhythmias, and CNS depression. Patients with additional risk factors are at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: DroPERidol may enhance the adverse/toxic effect of Metoclopramide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation, ventricular arrhythmias, including torsades de pointes, when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: DroPERidol may enhance the CNS depressant effect of Propofol. Propofol may enhance the QTc-prolonging effect of DroPERidol.  Management: Consider dose reductions of droperidol or propofol during coadministration due to additive effects on CNS depression. Also monitor for QTc prolongation and ventricular arrhythmia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of DroPERidol. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). QT-prolonging Antipsychotics (Moderate Risk) may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of DroPERidol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): DroPERidol may enhance the CNS depressant effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). DroPERidol may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Consider dose reductions and monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Saquinavir.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopental: DroPERidol may enhance the therapeutic effect of Thiopental.  Management: Consider thiopental dose reduction when used concomitantly with droperidol. Monitor patient response to treatment closely if using this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: DroPERidol may enhance the QTc-prolonging effect of Ziprasidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F163561"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Droperidol has been evaluated for the adjunctive management of hyperemesis gravidarum (Ferreira 2003; Nageotte 1996); however, use for the treatment of persistent symptoms of nausea and vomiting in pregnancy is not recommended (ACOG 189 2018).</p></div>
<div class="block brc drugH1Div" id="F20306060"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;">It is not known if droperidol is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Adverse events were observed in breastfed infants following maternal administration during cesarean delivery (based on Neurologic and Adaptive Capacity Scores); however, additional study is needed (Bonhomme 2002). Theoretically, droperidol may interfere with milk production. Although data is limited, infant exposure following a single maternal dose will limit the potential for adverse events in a breastfed infant (Spigset 1994). The manufacturer recommends that caution be exercised when administering droperidol to breastfeeding women.</p></div>
<div class="block mop drugH1Div" id="F163550"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">To identify QT prolongation, obtain a 12-lead ECG prior to use; continue monitoring ECG for 2 to 3 hours following administration. Vital signs; serum magnesium and potassium; mental status, abnormal involuntary movement scale (AIMS); observe for dystonias, extrapyramidal side effects, and temperature changes</p></div>
<div class="block pha drugH1Div" id="F163540"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Droperidol is a butyrophenone antipsychotic; antiemetic effect is a result of blockade of dopamine stimulation of the chemoreceptor trigger zone. Other effects include alpha-adrenergic blockade, peripheral vascular dilation, and reduction of the pressor effect of epinephrine resulting in hypotension and decreased peripheral vascular resistance; may also reduce pulmonary artery pressure</p></div>
<div class="block phk drugH1Div" id="F163557"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 3 to 10 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: ~30 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 2 to 4 hours, may extend to 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: Rapid (Cressman 1973)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Crosses blood-brain barrier (McKeage 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: Children: ~0.6 L/kg; Adults: ~1.5 L/kg (McKeage 2006)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 85% to 90% (McKeage 2006)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, to <i>p</i>-fluorophenylacetic acid, benzimidazolone, <i>p</i>-hydroxypiperidine</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children ~ 1.7 hours; Adults: ~2 hours (McKeage 2006)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (75%, &lt;1% as unchanged drug); feces (22%, 11% as unchanged drug) (McKeage 2006)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038606"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ponveridol | Xomolix</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">DROPERIDOL SXP</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dehydrobenzperidol | Droperidol kalceks</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Droperidol SINTETICA</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Xomolix</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Droperidol carino | Droperidol carinopharm | Droperidol panpharma | Droperidol rotexmedica | Ponveridol | Xomolix</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Droperidol aguettant | Droperidol panpharma</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Droperidol Hikma | Droperidol kalceks | Xomolix</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dehydrobenzperidol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Droleptan | Droperidol aguettant | Droperidol Arrow | Droperidol panpharma</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Droperidol panpharma | Xomolix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Xomolix</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Droperidol kalceks | Xomolix</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Xomolix</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Droperidolo hikma | Sintodian | Xomolix</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dehydrobenzperidol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dehydrobenzperidol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dehydrobenzper | Dehydrobenzperidol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dridol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Xomolix</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Droperidol Hikma | Droperidol panpharma | Xomolix</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Inapsine</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Doravit</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dridol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Xomolix</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dehydrobenzperidol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29266076">
<a name="29266076"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea and vomiting of pregnancy. <i>Obstet Gynecol</i>. 2018;131(1):e15-e30. doi: 10.1097/AOG.0000000000002456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/29266076/pubmed" id="29266076" target="_blank">29266076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15051578">
<a name="15051578"></a>American College of Obstetrics and Gynecology (ACOG), "ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: Nausea and Vomiting of Pregnancy," <i>Obstet Gynecol</i>, 2004, 103(4):803-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/15051578/pubmed" id="15051578" target="_blank">15051578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26287788">
<a name="26287788"></a>American College of Obstetrics and Gynecology (ACOG). Practice Bulletin No. 153: Nausea and Vomiting of Pregnancy. <i>Obstet Gynecol</i>. 2015;126(3):e12-e24. doi: 10.1097/AOG.0000000000001048.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/26287788/pubmed" id="26287788" target="_blank">26287788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bargiota.2013">
<a name="Bargiota.2013"></a>Bargiota SI, Bonotis KS, Messinis IE, Angelopoulos NV, eds. <i>Schizophrenia Research and Treatment</i>. The effects of antipsychotics on prolactin levels and women's menstruation. Hindawi Publishing Corporation; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bonhomme.2002">
<a name="Bonhomme.2002"></a>Bonhomme V, Brichant JF, Wuilmart M, et al. Droperidol reduces nausea after caesarean section but alters the neurological status of the breastfed infants. <i>Anesthesiology</i>. 2002;96(Sup 2):A1044.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25395689">
<a name="25395689"></a>Calver L, Drinkwater V, Gupta R, et al. Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomised controlled trial. <i>Br J Psychiatry</i>. 2015;206(3):223-228.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/25395689/pubmed" id="25395689" target="_blank">25395689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22981685">
<a name="22981685"></a>Chan EW, Taylor DM, Knott JC, et al. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. <i>Ann Emerg Med</i>. 2013;61(1):72-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/22981685/pubmed" id="22981685" target="_blank">22981685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12460844">
<a name="12460844"></a>Chase PB, Biros MH. A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. <i>Acad Emerg Med</i>. 2002;9(12):1402-1410. doi:10.1111/j.1553-2712.2002.tb01609.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/12460844/pubmed" id="12460844" target="_blank">12460844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32726229">
<a name="32726229"></a>Cole JB, Lee SC, Martel ML, Smith SW, Biros MH, Miner JR. The incidence of QT prolongation and torsades des pointes in patients receiving droperidol in an urban emergency department. <i>West J Emerg Med.</i> 2020;21(4):728-736. doi:10.5811/westjem.2020.4.47036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/32726229/pubmed" id="32726229" target="_blank">32726229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4707581">
<a name="4707581"></a>Cressman WA, Plostnieks J, Johnson PC. Absorption, metabolism and excretion of droperidol by human subjects following intramuscular and intravenous administration. <i>Anesthesiology</i>. 1973;38(4):363-369.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/4707581/pubmed" id="4707581" target="_blank">4707581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11063369">
<a name="11063369"></a>Dorfman DH. The use of physical and chemical restraints in the pediatric emergency department. <i>Pediatr Emerg Care</i>. 2000;16(5):355-360. doi:10.1097/00006565-200010000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/11063369/pubmed" id="11063369" target="_blank">11063369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AmericanRegent.1">
<a name="AmericanRegent.1"></a>Droperidol Injection [prescribing information]. Shirley, NY: American Regent, Inc; January 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Droperidol injection [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Droperidol Injection [product monograph]. Boucherville, QC, Canada: Sandoz Canada Inc; July 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ferreira.2003">
<a name="Ferreira.2003"></a>Ferreira E, Bussieres JF, Turcotte V, et al. Case–control study comparing droperidol plus diphenhydramine with conventional treatment in hyperemesis gravidarum. <i>Journal of Pharmacy Technology</i>. 2003;19(6):349-354. doi: 10.1177/875512250301900602.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26457577">
<a name="26457577"></a>Froes Brandao D, Strasser-Weippl K, Goss PE. Prolactin and breast cancer: The need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: A review. <i>Cancer</i>. 2016;122(2):184-188. doi:10.1002/cncr.29714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/26457577/pubmed" id="26457577" target="_blank">26457577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32467512">
<a name="32467512"></a>Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2020;131(2):411-448. doi:10.1213/ANE.0000000000004833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/32467512/pubmed" id="32467512" target="_blank">32467512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18042859">
<a name="18042859"></a>Gan TJ, Meyer TA, Apfel CC, et al, “Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,” <i>Anesth Analg.</i> 2007;105(6):1615-1628.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/18042859/pubmed" id="18042859" target="_blank">18042859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21053">
<a name="21053"></a>Ghoneim MM and Korttila K, “Pharmacokinetics of Intravenous Anaesthetics: Implications for Clinical Use,” <i>Clin Pharmacokinet</i>, 1977, 2(5):344-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/21053/pubmed" id="21053" target="_blank">21053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8232489">
<a name="8232489"></a>Grunberg SM and Hesketh PJ, “Control of Chemotherapy-Induced Emesis,” <i>N Engl J Med</i>, 1993, 329(24):1790-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/8232489/pubmed" id="8232489" target="_blank">8232489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10875717">
<a name="10875717"></a>Henzi I, Sonderegger J, Tramèr MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. <i>Can J Anaesth</i>. 2000;47(6):537-551. doi:10.1007/BF03018945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/10875717/pubmed" id="10875717" target="_blank">10875717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29095482">
<a name="29095482"></a>Herzig SJ, LaSalvia MT, Naidus E, et al. Antipsychotics and the risk of aspiration pneumonia in individuals hospitalized for nonpsychiatric conditions: a cohort study. <i>J Am Geriatr Soc</i>. 2017;65(12):2580-2586. doi: 10.1111/jgs.15066.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/29095482/pubmed" id="29095482" target="_blank">29095482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37317809">
<a name="37317809"></a>Hoffmann JA, Pergjika A, Liu L, Janssen AC, Walkup JT, Johnson JK, Alpern ER, Corboy JB. Standardizing and Improving Care for Pediatric Agitation Management in the Emergency Department. <i>Pediatrics</i>. 2023;152(1):e2022059586. doi: 10.1542/peds.2022-059586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/37317809/pubmed" id="37317809" target="_blank">37317809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20868907">
<a name="20868907"></a>Isbister GK, Calver LA, Page CB, et al. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. <i>Ann Emerg Med</i>. 2010;56(4):392-401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/20868907/pubmed" id="20868907" target="_blank">20868907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17519460">
<a name="17519460"></a>Jackson CW, Sheehan AH, and Reddan JG, “Evidence-Based Review of the Black-Box Warning for Droperidol”, <i>AJHP</i>, 2007, 64(11):1174-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/17519460/pubmed" id="17519460" target="_blank">17519460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9473921">
<a name="9473921"></a>Joshi PT, Hamel L, Joshi AR, Capozzoli JA. Use of droperidol in hospitalized children. <i>J Am Acad Child Adolesc Psychiatry</i>. 1998;37(2):228-230. doi:10.1097/00004583-199802000-00017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/9473921/pubmed" id="9473921" target="_blank">9473921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12658255">
<a name="12658255"></a>Kao LW, Kirk MA, Evers SJ, et al, “Droperidol, QT Prolongation, and Sudden Death: What Is the Evidence,” <i>Ann Emerg Med</i>, 2003, 41(4):546-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/12658255/pubmed" id="12658255" target="_blank">12658255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27976370">
<a name="27976370"></a>Khokhar MA, Rathbone J. Droperidol for psychosis-induced aggression or agitation. <i>Cochrane Databasse Syst Rev</i>. 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/27976370/pubmed" id="27976370" target="_blank">27976370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16387219">
<a name="16387219"></a>Knott JC, Taylor DM, Castle DJ. Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. <i>Ann Emerg Med</i>. 2006;47:61-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/16387219/pubmed" id="16387219" target="_blank">16387219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15972615">
<a name="15972615"></a>Landi F, Onder G, Cesari M, Barillaro C, Russo A, Bernabei R; Silver Network Home Care Study Group. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. <i>J Gerontol A Biol Sci Med Sci</i>. 2005;60(5):622-6226. doi:10.1093/gerona/60.5.622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/15972615/pubmed" id="15972615" target="_blank">15972615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16670360">
<a name="16670360"></a>Leslie JB and Gan TJ, “Meta-Analysis of the Safety of 5-HT3 Antagonists With Dexamethasone or Droperidol for Prevention of PONV," <i>Ann Pharacother</i>, 2006, 40(5):856-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/16670360/pubmed" id="16670360" target="_blank">16670360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10470391">
<a name="10470391"></a>Lim BS, Pavy TJ, Lumsden G. The antiemetic and dysphoric effects of droperidol in the day surgery patient. <i>Anaesth Intensive Care</i>. 1999;27(4):371-374. doi:10.1177/0310057X9902700407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/10470391/pubmed" id="10470391" target="_blank">10470391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15138897">
<a name="15138897"></a>Maddalena AS, Fox M, Hofmann M, et al. Esophageal dysfunction on psychotropic medication. A case report and literature review. <i>Pharmacopsychiatry</i>. 2004;37(3):134-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/15138897/pubmed" id="15138897" target="_blank">15138897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16282517">
<a name="16282517"></a>Martel M, Sterzinger A, Miner J, et al. Management of acute undifferentiated agitation in the emergency department: A randomized, double-blind trial of droperidol, ziprasidone and midazolam. <i>Acad Emerg Med</i>. 2005;12(12):1167-1172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/16282517/pubmed" id="16282517" target="_blank">16282517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17112307">
<a name="17112307"></a>McKeage K, Simpson D, Wagstaff AJ. Intravenous droperidol: a review of its use in the management of postoperative nausea and vomiting. <i>Drugs</i>. 2006;66(16):2123-2147. doi:10.2165/00003495-200666160-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/17112307/pubmed" id="17112307" target="_blank">17112307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3415026">
<a name="3415026"></a>Melnick BM. Extrapyramidal reactions to low-dose droperidol. <i>Anesthesiology</i>. 1988;69(3):424-426. doi:10.1097/00000542-198809000-00027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/3415026/pubmed" id="3415026" target="_blank">3415026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mokha.1">
<a name="Mokha.1"></a>Mokha J. Vomiting and nausea. In: Wyllie R, Hyams JS, Kay M, eds. <i>Pediatric Gastrointestinal and Liver Disease</i>. 6th ed. Elsevier; 2020:chap 8.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8678143">
<a name="8678143"></a>Nageotte MP, Briggs GG, Towers CV, Asrat T. Droperidol and diphenhydramine in the management of hyperemesis gravidarum. <i>Am J Obstet Gynecol</i>. 1996;174(6):1801-1805; discussion 1805-1806.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/8678143/pubmed" id="8678143" target="_blank">8678143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17893447">
<a name="17893447"></a>Nuttall G, Eckerman K, Jacob K, et al, “Does Low-dose Droperidol Administration Increase the Risk of Drug-Induced QT Prolongation and Torsade de Pointes in the General Surgical Population?” <i>Anesthesiology</i>, 2007, 107(4):531-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/17893447/pubmed" id="17893447" target="_blank">17893447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30380965">
<a name="30380965"></a>Page CB, Parker LE, Rashford SJ, Isoardi KZ, Isbister GK. A prospective study of the safety and effectiveness of droperidol in children for prehospital acute behavioral disturbance. <i>Prehosp Emerg Care</i>. 2019;23(4):519-526. doi:10.1080/10903127.2018.1542473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/30380965/pubmed" id="30380965" target="_blank">30380965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2880887">
<a name="2880887"></a>Peabody CA, Warner MD, Whiteford HA, et al, “Neuroleptics and the Elderly,” <i>J Am Geriatr Soc</i>, 1987, 35(3):233-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/2880887/pubmed" id="2880887" target="_blank">2880887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25837231">
<a name="25837231"></a>Perkins J, Ho JD, Vilke GM, DeMers G. American Academy of Emergency Medicine Position Statement: Safety of Droperidol Use in the Emergency Department. <i>J Emerg Med</i>. 2015;49(1):91-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/25837231/pubmed" id="25837231" target="_blank">25837231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35490341">
<a name="35490341"></a>Ramsden SC, Pergjika A, Janssen AC, et al. A systematic review of the effectiveness and safety of droperidol for pediatric agitation in acute care settings. <i>Acad Emerg Med</i>. 2022;29(12):1466-1474. doi:10.1111/acem.14515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/35490341/pubmed" id="35490341" target="_blank">35490341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10340682">
<a name="10340682"></a>Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. <i>J Clin Psychiatry</i>. 1999;60(suppl 10):5-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/10340682/pubmed" id="10340682" target="_blank">10340682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9017481">
<a name="9017481"></a>Rosen CL, Ratliff AF, Wolfe RE, Branney SW, Roe EJ, Pons PT. The efficacy of intravenous droperidol in the prehospital setting. <i>J Emerg Med</i>. 1997;15(1):13-17. doi:10.1016/s0736-4679(96)00259-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/9017481/pubmed" id="9017481" target="_blank">9017481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1681122">
<a name="1681122"></a>Saltz BL, Woerner MG, Kane JM, et al, “Prospective Study of Tardive Dyskinesia Incidence in the Elderly,” <i>JAMA</i>, 1991, 266(17):2402-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/1681122/pubmed" id="1681122" target="_blank">1681122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Seifert.1984">
<a name="Seifert.1984"></a>Seifert RD. Therapeutic Drug Monitoring: Psychotropic Drugs. <i>J Pharm Pract.</i> 1984;6:403-416.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29402652">
<a name="29402652"></a>Seppala LJ, Wermelink AMAT, de Vries M, et al; EUGMS task and Finish group on fall-risk-increasing drugs. Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics. <i>J Am Med Dir Assoc</i>. 2018;19(4):371.e11-371.e17. doi:10.1016/j.jamda.2017.12.098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/29402652/pubmed" id="29402652" target="_blank">29402652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11406684">
<a name="11406684"></a>So PC. Neuroleptic malignant syndrome induced by droperidol. <i>Hong Kong Med J</i>. 2001;7(1):101-103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/11406684/pubmed" id="11406684" target="_blank">11406684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17390261">
<a name="17390261"></a>Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/17390261/pubmed" id="17390261" target="_blank">17390261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8171959">
<a name="8171959"></a>Spigset O. Anaesthetic agents and excretion in breast milk. <i>Acta Anaesthesiol Scand</i>. 1994;38(2):94-103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/8171959/pubmed" id="8171959" target="_blank">8171959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3280112">
<a name="3280112"></a>Sridhar KS and Donnelly E, “Combination Antiemetics for Cisplatin Chemotherapy,” <i>Cancer</i>, 1988, 61(8):1508-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/3280112/pubmed" id="3280112" target="_blank">3280112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20401969">
<a name="20401969"></a>Szwak K, Sacchetti A. Droperidol use in pediatric emergency department patients. <i>Pediatr Emerg Care</i>. 2010;26(4):248-250. doi:10.1097/pec.0b013e3181d6d9f2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/20401969/pubmed" id="20401969" target="_blank">20401969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34277183">
<a name="34277183"></a>Takechi K, Shimizu I. Delayed ventricular tachycardia after prophylactic doses of droperidol in patients with mild QT interval prolongation due to preoperative medication. <i>Cureus</i>. 2021;13(6):e15560. doi:10.7759/cureus.15560<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/34277183/pubmed" id="34277183" target="_blank">34277183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27745766">
<a name="27745766"></a>Taylor DM, Yap CY, Knott JC, et al. Midazolam-droperidol, droperidol, or olanzapine for acute agitation: a randomized clinical trial. <i>Ann Emerg Med</i>. 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/27745766/pubmed" id="27745766" target="_blank">27745766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1554179">
<a name="1554179"></a>Thomas H, Schwartz E, Petrilli R. Droperidol versus haloperidol for chemical restraint of agitated and combative patients. <i>Ann Emerg Med</i>. 1992;21:407-413.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/1554179/pubmed" id="1554179" target="_blank">1554179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2190193">
<a name="2190193"></a>Tortorice PV and O'Connell MB, “Management of Chemotherapy-Induced Nausea and Vomiting,” <i>Pharmacotherapy</i>, 1990, 10(2):129-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/2190193/pubmed" id="2190193" target="_blank">2190193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17200430">
<a name="17200430"></a>Wilhelm SM, Dehoorne-Smith ML, and Kale-Pradhan PB, “Prevention of Postoperative Nausea and Vomiting,” <i>Ann Pharmacother</i>, 2007, 41(1):68-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/droperidol-drug-information/abstract-text/17200430/pubmed" id="17200430" target="_blank">17200430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wilson.1981">
<a name="Wilson.1981"></a>Wilson J, Weltz M, Solimando D, et al, “Continuous Infusion Droperidol: Antiemetic Therapy for Cis-Platinum (DDP) Toxicity,” <i>Proc Am Soc Clin Oncol</i>, 1981, C-351.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9395 Version 346.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
